@kellswelljourney's GLP-1 content needs fact-checking

What does this video actually claim?

Without access to the specific video content from @kellswelljourney, we can't analyze the exact claims made about GLP-1 medications. This TikTok appears in the GLP-1 category, suggesting it discusses semaglutide, tirzepatide, or similar medications used for weight management.

The creator's handle suggests a wellness journey focus, which often includes personal experience content about weight loss medications. These videos typically cover topics like dosing, side effects, weight loss results, or lifestyle changes while using GLP-1 receptor agonists.

We'll focus on common claims made about these medications that frequently appear in social media content, particularly around effectiveness, safety, and practical usage tips.

What do the clinical trials actually show?

The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss at 68 weeks with 2.4mg semaglutide versus 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed even better results with tirzepatide: 20.9% weight loss at 72 weeks with the 15mg dose.

These aren't small studies. STEP 1 included 1,961 participants, while SURMOUNT-1 enrolled 2,539 people. Both trials required participants to also follow reduced-calorie diets and increase physical activity.

Side effects are real and common. In STEP 1, 74.2% of semaglutide users experienced gastrointestinal adverse events compared to 47.9% on placebo. The most frequent were nausea, diarrhea, and vomiting.

What gets misrepresented on social media?

TikTok creators often skip the diet and exercise requirements from clinical trials. The STEP and SURMOUNT studies didn't test these medications alone. They tested them alongside 500-calorie daily deficits and 150 minutes of weekly physical activity.

Many videos also downplay discontinuation rates. In STEP 1, 17.3% of semaglutide users dropped out due to adverse events versus 8.2% on placebo. That's nearly one in five people who couldn't tolerate the medication.

Starting dose timelines get confused too. Semaglutide begins at 0.25mg weekly for four weeks, then 0.5mg for four weeks, before reaching the 1mg therapeutic dose. Tirzepatide starts at 2.5mg and escalates over 16-20 weeks to reach maximum doses.

What should you actually know about GLP-1s?

These medications work by slowing gastric emptying and affecting brain appetite centers. They're not appetite suppressants in the traditional sense. They change how your body processes food and hunger signals.

Insurance coverage remains complicated. Wegovy (semaglutide for weight loss) costs around $1,300 monthly without coverage. Ozempic (semaglutide for diabetes) is often covered but using it off-label for weight loss can create access issues.

Weight regain happens when you stop. The STEP 1 extension study showed participants regained about two-thirds of lost weight within a year of discontinuation. This isn't a character flaw. It's how these medications work.

Individual results vary significantly, despite what social media suggests. Not everyone achieves the trial averages, and some people don't respond at all.